Immunotherapy in frail non-small-cell lung cancer patients

doi:10.1016/S0140-6736(24)00792-X

Comment

. 2024 May 18;403(10440):1986.

doi: 10.1016/S0140-6736(24)00792-X.

Immunotherapy in frail non-small-cell lung cancer patients

Rolof Gp Gijtenbeek¹, Anneloes L Noordhof², Oke D Asmara², Harry Jm Groen³, Wouter H van Geffen²

Affiliations

¹ Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden 8934 AD, Netherlands. Electronic address: rolof.gijtenbeek@mcl.nl.
² Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden 8934 AD, Netherlands.
³ Department of Pulmonary Diseases, University Medical Center Groningen and University of Groningen, Groningen, Netherlands.

PMID: 38762321
DOI: 10.1016/S0140-6736(24)00792-X

Comment

Immunotherapy in frail non-small-cell lung cancer patients

Rolof Gp Gijtenbeek et al. Lancet. 2024.

. 2024 May 18;403(10440):1986.

doi: 10.1016/S0140-6736(24)00792-X.

Authors

Rolof Gp Gijtenbeek¹, Anneloes L Noordhof², Oke D Asmara², Harry Jm Groen³, Wouter H van Geffen²

Affiliations

¹ Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden 8934 AD, Netherlands. Electronic address: rolof.gijtenbeek@mcl.nl.
² Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden 8934 AD, Netherlands.
³ Department of Pulmonary Diseases, University Medical Center Groningen and University of Groningen, Groningen, Netherlands.

PMID: 38762321
DOI: 10.1016/S0140-6736(24)00792-X

No abstract available

PubMed Disclaimer

Comment on

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.

Cited by

Stage III NSCLC treatment options: too many choices.
Asmara OD, Hardavella G, Ramella S, Petersen RH, Tietzova I, Boerma EC, Tenda ED, Bouterfas A, Heuvelmans MA, van Geffen WH. Asmara OD, et al. Breathe (Sheff). 2024 Oct 1;20(3):240047. doi: 10.1183/20734735.0047-2024. eCollection 2024 Oct. Breathe (Sheff). 2024. PMID: 39360027 Free PMC article. Review.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy in frail non-small-cell lung cancer patients

Affiliations

Immunotherapy in frail non-small-cell lung cancer patients

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical